The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Open accessAbstract
Purpose: For a comprehensive overview of the genetic alterations of neuroblastoma, their association and clinical significance, we conducted a whole-genome DNA copy number analysis. Patients and Methods: A series of 493 neuroblastoma (NB) samples was investigated by array-based comparative genomic hybridization in two consecutive steps (224, then 269 patients). Results: Genomic analysis identified several types of profiles. Tumors presenting exclusively whole-chromosome copy number variations were associated with excellent survival. No disease-related death was observed in this group. In contrast, tumors with any type of segmental chromosome alterations characterized patients with a high risk of relapse. Patients with both numerical and segmental abnormalities clearly shared the higher risk of relapse of segmental-only patients. In a multivariate analysis, taking into account the genomic profile, but also previously described individual genetic and clinical markers with prognostic significance, the presence of segmental alterations with (HR, 7.3; 95% CI, 3.7 to 14.5; P < .001) or without MYCN amplification (HR, 4.5; 95% CI, 2.4 to 8.4; P < .001) was the strongest predictor of relapse; the other significant variables were age older than 18 months (HR, 1.8; 95% CI, 1.2 to 2.8; P = .004) and stage 4 (HR, 1.8; 95% CI, 1.2 to 2.7; P = .005). Finally, within tumors showing segmental alterations, stage 4, age, MYCN amplification, 1p and 11q deletions, and 1q gain were independent predictors of decreased overall survival. Conclusion: The analysis of the overall genomic pattern, which probably unravels particular genomic instability mechanisms rather than the analysis of individual markers, is essential to predict relapse in NB patients. It adds critical prognostic information to conventional markers and should be included in future treatment stratification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Neuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
The International Neuroblastoma Pathology Classification (the Shimada system)
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 · Cited by 1,067
Kallioniemi, O., Kallioniemi, A., Piper, J., Isola, J., Waldman, F. M., Gray, J. W., & Pinkel, D. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870100403 · Cited by 1,012
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions
Hupé, P., Stransky, N., Thiery, J.-P., Radvanyi, F., & Barillot, E. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth418 · Cited by 521
Look, A. T., Hayes, F. A., Nitschke, R., McWilliams, N. B., & Green, A. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198407263110405 · Cited by 491
Allelic Loss of Chromosome 1p as a Predictor of Unfavorable Outcome in Patients with Neuroblastoma
Caron, H. N., Sluis, P. V., de Kraker, J., Bökkerink, J. P. M., Egeler, M., Laureys, G., Slater, R. M., Westerveld, A., Voûte, P. A., & Versteeg, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340404 · Cited by 425
Selzer, R. R., Richmond, T. A., Pofahl, N. J., Green, R. D., Eis, P. S., Nair, P., Brothman, A. R., & Stallings, R. L. (2005) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20243 · Cited by 266
Mehta, C. R., & Patel, N. R. (1986) · ACM Transactions on Mathematical Software · doi:10.1145/6497.214326 · Cited by 203
Two types of chromosome 1p losses with opposite significance in gliomas
Idbaih, A., Marie, Y., Pierron, G., Brennetot, C., Hoang-Xuan, K., Kujas, M., Mokhtari, K., Sanson, M., Lejeune, J., Aurias, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20607 · Cited by 167
Self-citationStallings, R. L., Nair, P., Maris, J. M., Catchpoole, D. R., McDermott, M., O’Meara, A., & Breatnach, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4154 · Cited by 119
Idbaïh, A., Marie, Y., Lucchesi, C., Pierron, G., Manié, É., Raynal, V., Mosseri, V., Hoang‐Xuan, K., Kujas, M., Brito, I., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23270 · Cited by 117
Self-citationGenome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays
George, R. E., Attiyeh, E. F., Li, S., Moreau, L. A., Neuberg, D. S., Li, C., Fox, E. A., Meyerson, M. M., Diller, L., Fortina, P. M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000255 · Cited by 117
Kallioniemi, A. H. (2008) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.11.004 · Cited by 116
VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles
Rosa, P. L., Viara, E., Hupé, P., Pierron, G., Liva, S., Neuvial, P., Brito, I., Lair, S., Servant, N., Robine, N., et al. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl359 · Cited by 111
Self-citationMossé, Y. P., Diskin, S. J., Wasserman, N. F., Rinaldi, K., Attiyeh, E. F., Cole, K. A., Jagannathan, J., Bhambhani, K., Winter, C. L., & Maris, J. M. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20477 · Cited by 110
A remark on algorithm 643: FEXACT
Clarkson, D. B., Fan, Y.-A., & Joe, H. (1993) · ACM Transactions on Mathematical Software · doi:10.1145/168173.168412 · Cited by 106
(SFCE), O. B. O. T. S. F. D. C. D. L., Schleiermacher, G., Michon, J. M., Huon, I., d’Enghien, C. D., Klijanienko, J., Brisse, H. J., Ribeiro, A., Mosseri, V., Rubie, H., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603820 · Cited by 96
Self-citationTomioka, N., Oba, S., Ohira, M., Misra, A., Fridlyand, J., Ishii, S., Nakamura, Y., Isogai, E., Hirata, T., Yoshida, Y., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210661 · Cited by 80
Jong, K., Marchiori, E., van der Vaart, A., Chin, S.-F., Carvalho, B. G., Tijssen, M., Eijk, P. P., van den IJssel, P., Grabsch, H. I., Quirke, P., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209919 · Cited by 42
High-resolution array CGH increases heterogeneity tolerance in the analysis of clinical samples
Garnis, C., Coe, B. P., Lam, S. C., MacAulay, C. E., & Lam, W. L. (2005) · Genomics · doi:10.1016/j.ygeno.2005.02.015 · Cited by 35
Carr, J., Bown, N. P., Case, M. C., Hall, A. G., Lunec, J., & Tweddle, D. A. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.08.012 · Cited by 34
Schleiermacher, G., Bourdeaut, F., Combaret, V., Picrron, G., Raynal, V., Aurias, A., Ribeiro, A., Janoueix‐Lerosey, I., & Delattre, O. (2005) · Oncogene · doi:10.1038/sj.onc.1208486 · Cited by 32
Self-citationPreferential Occurrence of Chromosome Breakpoints within Early Replicating Regions in Neuroblastoma
Janoueix‐Lerosey, I., Hupé, P., Maciorowski, Z., Rosa, P. L., Schleiermacher, G., Pierron, G., Liva, S., Barillot, E., & Delattre, O. (2005) · Cell Cycle · doi:10.4161/cc.4.12.2257 · Cited by 31
Self-citationHoebeeck, J., Michels, E., Menten, B., Roy, N. V., Eggert, A., Schramm, A. R., Preter, K. D., Yigit, N., Smet, E. D., Paepe, A. D., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22326 · Cited by 24
Self-citation
Cited by
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Self-citationSequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 870
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3580 · Cited by 645
Williamson, D., Missiaglia, E., de Reyniès, A., Pierron, G., Thuille, B., Palenzuela, G., Thway, K., Orbach, D., Laé, M., Fréneaux, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3814 · Cited by 502
Self-citation
Metadata
- Authors
- Janoueix-Lerosey, I., Schleiermacher, G., Michels, E., Mosseri, V., Ribeiro, A., Lequin, D., Vermeulen, J., Couturier, J., Peuchmaur, M., Valent, A., Plantaz, D., Rubie, H., Valteau-Couanet, D., Thomas, C., Combaret, V., Rousseau, R., Eggert, A., Michon, J., Speleman, F., & Delattre, O.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-03-01
- Volume
- 27
- Issue
- 7
- Pages
- 1026-1033
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131776400
- Cited by
- 349
- References
- 28
- FWCI
- 18.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.